St Stephen’s Centre, 369 Fulham Road, London SW10 9NH
Tel: 020 3315 6136
www.ssat.org.uk

Registered Charity: 11034163
Registered in England Company Number: 7134218
INTRODUCTION

The St Stephen’s AIDS Trust is a UK clinical research charity based at the Chelsea and Westminster Hospital in London.

The Charity was founded in 1991 by Professor Brian Gazzard and a team of colleagues in response to the HIV/AIDS global pandemic and its impact on people affected by and living with HIV in the United Kingdom.

St Stephen’s AIDS Trust mission statement is to:
“promote clinical research into the treatment of HIV and those infections and malignancies associated with the acquired immunodeficiency syndrome (AIDS), in particular the research undertaken at the Chelsea and Westminster Hospital, and to publish such research. It also promotes education regarding all aspects and matters relating to HIV by providing information, training and advice throughout the world”.

Over the last 30 years the Charity has been at the forefront of clinical research studies, from the early nucleoside reverse transcriptase inhibitor studies in the 1980s, to the current range of successful highly active anti-retroviral therapy studies. The Charity's research activities have produced, in the last 10 years alone, over 500 clinical research papers. A selection of some 300 of these papers has been collected together in this publication.

Charity has developed a strong track record in clinical research through the continued investment in its research infrastructure and capability, such as its dedicated Phase I-IV PK and Clinical Trials Unit at the Chelsea and Westminster Hospital. As well as these physical facilities, the Charity has the capability to sponsor and manage multi-centred clinical research studies, in the UK and internationally, through its established service teams in regulatory, compliance, project management, logistics, data management and statistics. A range of leading medical and scientific experts in HIV medicine, immunology and infectious diseases supports this infrastructure and capability in clinical research.

As the selection of papers included in this publication suggest, the Charity has successfully managed a diverse range of relationships and partnerships. These include many international pharmaceutical companies; a number of influential global NGO’s (Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative); key UK public research bodies (MRC, NHIR, Public Health); academic institutions from the UK and across the world; and, as equally important, individual researchers, scientists and clinicians.

If you are interested in finding out more about the work of the Charity, exploring possible clinical research collaborations and partnerships or accessing its managed services for conducting clinical research in the UK and internationally, please contact:

General (Charity) enquiries: Linda Connor, Admin Manager: 020 3315 6136
PK and Clinical Trials Unit: Carl Fletcher, Associate Director: 020 3325 6325
Clinical Research Organisation Services: Ruth Bateson, Associate Director: 020 3315 6563
2014


British HIV Association Guidelines for the treatment of HIV 1 positive adults with Antiretroviral therapy 2012 (updated 2013)
HIV Med 2014 Mar; 15 supp 2. 1-9

Clinical factors that predict noncirrhotic portal hypertension in HIV infected patients: Proposed diagnostic algorithm
J Infect Dis 2014 Mar; 209 (5): 734-8

Chacko L, Chamberlain F, Mandalia S, Nelson M
Do resistance patterns vary between different FTC contain drug regimens?
J Infect 2014 Feb 8 2014

Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy.
HIV Medicine 2014, 15 (suppl 3) 53

Chacko L, Chamberlain F, Mandalia S, Nelson M
Five-year safety evaluation of Maraviroc in HIV 1 infected treatment experienced patients
J Acqui Immune Defic Syndr 2014 Jan 1; 65 (1): 78-81

HIV-related neurocognitive impairment screening: the patient’s perspective on its utility and psychological impact.
AIDS Care. 2014 Mar 13

Immunological function in HIV-seronegative men who have sex with men (MSM) and Kaposi’s sarcoma (KS)
HIV Medicine 2014, 15 (suppl 3) 55.

Impact on life expectancy of HIV 1 positive individuals of CD4+ cell count and Viral load response to antiretroviral therapy; UK cohort study
AIDS 2014 Feb 19

Longley J, Redlin S, Balachandran K, Holmes P, Nelson M & Bower M.
Non-Hodgkin’s lymphoma (NHL): Does being on cART before diagnosis make a difference?
HIV Medicine 2014, 15 (suppl 3) 55

Tull T, Papineni P, Cook C, Mee J, Bower M, Morar N, Nelson M
Paraneoplastic pemphigus in patient infected with HIV

Raman L, Nelson M
Prospective stage stratified approach to AIDS related Kaposi’s Sarcoma
J Clin Virol 2014 Feb 2

Smith M, Pealing J, McCann S, Balachandran K, Nelson M & Bower M
Second malignancies in patients with Kaposi’s sarcoma (KS): Does systemic chemotherapy contribute to risk?
HIV Medicine 2014, 15 (suppl 3) 8.

Shigella flexneri enteritis in risk- taking HIV infected MSM
J Infect 2014 Jan; 68 (1); 103-4

Ferras Alwan, Annie He, Silvia Montoto, Shireen Kassam, Matthew Mee, Fiona Burns, Simon Edwards, Andy Wilson, Melinda Tenant-Flowers, Robert Marcus, Kirit M. Ardeshna, Mark Bower, Kate Cwynarski.
The addition of Rituximab to CODOX-M/IVAC chemotherapy in the treatment of Burkitt lymphoma is safe and associated with increased efficacy in the HIV positive population.
EHA 2014.

Bulteel N, Banso-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Nelson M, CHIC study group; UK Drug resistant Database (UK HDRD) Study Group
The emergence of drug resistant HIV variants at virological failure of HAART combination containing efavirenz, Tenofovir and lamivudine or emtricitabine within the UK collaborative HIV cohort
J Infect 2014 Jan; 68 (1): 77-84
2013


A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered Ex Vivo to Autologous White Blood Cells in HIV-Infected Individuals.


96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naïve, HIV-1-infected adults: ASSERT study.

Antivir Ther. 2013 Jul 31

Pozniak AL, Arribas JR.

A benchmark for management of drug resistant HIV.


A retrospective multi-centre analysis of treatment intensification for HIV positive patients with high risk diffuse large B cell lymphoma

Leuk Lymphoma 2013 Sep; 54 (9): 1921-7

Martin TC, Martin NK, Naresh KN, Nelson M

A traumatic splenic rupture secondary to chronic HIV infection

Int J STD AIDS 2013 Dec; 24 (12): 989-91


An update to the HIV - TrePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes

J Antimicrob Chemother 2013 Nov 24

Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D, Kingston MA, Thng C, McCormack S, Gill ON, Nardone A; Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England

Sex Transm Infect 2013; 89:404-8


Automatic Oral Fluid-Based HIV Testing in HIV Screening Programmes

HIV Med 2013; 14 Suppl 3:49-52

Abdel Malek R, Cox S, Bower M, Farag D & Alsirafy S.

Availability of informal caregivers for palliative care patients with cancer: Is there a difference between higher and lower income settings?


Mehta P, Nelson M, Brand A, Boag F

Avascular necrosis in HIV

Hematol Int. 2013 Jan; 33 (1): 235-8


Can we stop CD4+ testing in patients with HIV 1 RNA suppression on antiretroviral treatment?

AIDS 2013 Nov 13; 27 (17): 2759-63

Jagit Singh GK, Ijaz S, Rockwood N, Farnworth SP, Devitt E, Atkins M, TedderR, Nelson M.

Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV

J. Infect 2013 Jan; 66 (1): 103-6


Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics


Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV Type 1-Infected Patients: Week 48 Results.


Comparison of two diagnostic criteria schemes for multicentric Castleman’s disease in 72 cases.

HIV Medicine 2013, 14 (suppl 2) 28
2013 continued


Computation models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource limited settings

J Antimicrob Chemother 2013 June; 68 (6); 1406-14

Raben D, Delpech V, de Wit J, Sullivan A, Lazarus J, Dedes N, Coenen T, Lundgren J;

Conclusions from the HIV in Europe Copenhagen 2012 Conference and ways forward: working together for optimal HIV testing and earlier care


Rice B, Elford J, Yin Z, Kruijshaar M, Abubakar I, Lipman M, Pozniak A, Kall M, Delpech V.

Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales.


Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study


Beckett H, Abdul-Latif M, Mandalia S, Singh GKJ, Bower M & Nelson M.

Effect of bisphosphonates on the treatment of BMD abnormalities in an HIV-1 minfected cohort

HIV Medicine 2013, 14 (suppl 2) 39


Effects of age on antiretroviral plasma drug concentration in HIV infected subjects undergoing routine therapeutic drug monitoring

J Antimicrob Chemother 2013 June 68 (6) 1354-9


Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial


Nithianathan V, Singh GKJ, Bower M & Nelson M

Emerging patterns of integrase inhibitor resistance

HIV Medicine 2013, 14 (suppl 2) 24


Failure to achieve a CD4+ cell count response in combination antiretroviral therapy despite consistent viral load suppression

AIDS 2013 Dec 11

Rayment M, Sullivan AK

Failure to test for HIV infection; A medicolegal question?

Casebook 2013 21; 1: 7


Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study


F-FDG PET/CT in HIV related central nervous system pathology

Eur J Nucl Med Mol Imaging 2013 Sept; 40 (9); 1420 -7


Genetic determinants of idiopathic noncirrhotic ports hypertension in HIV infected patients

Clin Infect Dis 2013 April; 56 (8): 1117 - 22
Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D, Kingston MA, Thng C, McCormack S, Gill ON, Nardone A; GUMNet

**Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England**

*Sex Transm Infect* 2013; 89:404-8

C. Cevik M, Oh K, Scott S, Tan J, Bower M & Nelson M

**Hepatic safety profile of antiretrovirals in individuals infected with HIV and chronic hepatitis**

*HIV Medicine* 2013, 14 (suppl 2) 70

Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R; Gazzard BG, Nelson M

**Hepatitis C Virus reinfection incidence and treatment outcomes among HIV positive MSM**

*AIDS* 2013 Oct 23; 27 (16): 2551-7


**HIV status does not influence the outcome of patients diagnosed with DLBCL treated with R-CHOP in the HAART era**

*Haematologica, 2013; 98 (s1) 129.*


**HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient sub-groups.**

*Antivir Ther. 2013 Mar 21*

Lawton MD, Nathan M, Asboe D.

**HPV vaccination to prevent anal cancer in men who have sex with men**

*Sex Transm Infect. 2013 Aug;89(5):342-3.*


**INSIGHT SMART Study Team. HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation.**

*J Am Heart Assoc 2013; 2(4):e000264*

Bashford J, Nelson M, Bower M, Atkins M

**JC – a forgotten foe or a foe to be forgotten**

*IV Med 2013 May; 14 (5): 326*


**Kidney transplantation in HIV-positive adults: The UK experience.**

*Int J STD AIDS,*

Bull L, Bower M & Nelson M.

**Long-term therapeutic success of etravirine in switch and naive patients.**

*HIV Medicine 2013, 14 (suppl 2) 57*

Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ, Andersen O, Imami N

**Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.**


**Lymphogranuloma venereum diagnoses among men who have sex with men in the UK: interpreting a cross-sectional study using an epidemic phase-specific framework.**

*Sex Transm Infect 2013 Jul 12*

Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G, Carne S, Back DJ, Gill ON

**Non-disclosure of HIV status in UK sexual health clinics - a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey**

*Sex Transm Infect 2013; 89:120-1. Epub 2013 Feb 13*

Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M; Gazzard BG

**Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned**

*HIV Med 2013 March; 14 (3): 161-6*
2013 continued

Persistence of anal dysplasia following chemoradiotherapy for anal cancer
HIV Medicine 2013, 14 (suppl 2) 28

Persistence of HIV-1 Transmitted Drug Resistance Mutations

Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JS, Lane HC, Larder BA

Cevik M, Dickinson L, Singh GS, Bower M & Nelson M
Raltegravir (RAL) switch improves hepatitis C transaminits in HIV-1 and hepatitis C (HCV) co-infected individuals.
HIV Medicine 2013, 14 (suppl 2) 71.

Rilpivirine versus efavirenz in HIV1 infected subjects receiving emtricitabine/Tenofovir DF: pooled 96 week data from ECHO and THRIVE studies
HIV Clin Trials 2013 May-June; 14 (3): 81-91

Routine HIV Testing in the Emergency Department: Tough Lessons in Sustainability

The HSV 040 Vaccine Study Group
Safety and Immunogenicity of a glycoprotein D genital Herpes subunit vaccine in healthy 10-17 years of age. Results from a randomised controlled double blind trial.
Vaccine 2013 July 9. 50264-410X|13. 891-8

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults

Alfa-Wali M, Safarfashandi L, Ion L, Nelson M, Allen-Mersh T & Bower M.
Salvage surgery for residual primary anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
HIV Medicine 2013, 14 (suppl 2) 28

Bull L, Bower M & Nelson M.
Salvage therapy with protease inhibitor sparing regimens containing etravirine
HIV Medicine 2013, 14 (suppl 2) 60.

Screening for HIV-related neurocognitive impairment in clinical practice: Challenges and opportunities.
AIDS Care. 2013 Jul 22

Waters L, Bans L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug Resistance Database.
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.

Abdul-Latif M, Beckett H, Rayment M, Singh GKJ, Bower M & Nelson M.
Shigella Flexneri enteritis in risk-taking HIV-infected MSM - a single institution experience
HIV Medicine 2013, 14 (suppl 2) 76.

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations


The role of interleukin-6 and Interleukin-6 receptor in multicentric Castleman's disease: Frequency of polymorphism

HIV Medicine 2013, 14 (suppl 2) 26


The spectrum of non-AIDS defining malignancy: 431 cases

HIV Medicine 2013, 14 (suppl 2) 27

Chamberlain FE, Chacko L, Singh GKJ, Bower M & Nelson M

The use of azathioprine in HIV-infected individuals

HIV Medicine 2013, 14 (suppl 2) 65

Vishwanath V, Singh GKJ, Dub S, Bower M & Nelson M

The use of dual maraviroc/ritonavir boosted darunavir combination in clinical practice

HIV Medicine 2013, 14 (suppl 2) 59

Constandinou T, Vekeria S, Singh GKJ, Bower M & Nelson M

Use of antacid preparations with HAART

HIV Medicine 2013, 14 (suppl 2) 5


HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation

J Am Heart Assoc 2013; 2(4):e000264


A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.

Antivir Ther. 2012. [Epub ahead of print]

Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK, Vanhove GF; For the NGX-4010 C119 Study Group

A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy.


Are long-term non-progressors very slow progressors? Insights form the Chelsea & Westminster HIV cohort 1988-2010


Baseline data from the MSM Neurocog study


Ahmed A, Page E, Bower M & Nelson M.

Bocepravir for the treatment of chronic hepatitis C in HIV co-infected.

HIV Medicine 2012, 13 (suppl 1) 41

Scourfield A, Waters L, Martin T, Mandalia S, Bower M, Gazzard B & Nelson M.

Can antiretrovirals increase the risk of venous thromboembolism in HIV infection?

HIV Medicine 2012, 13 (suppl 1) 56.

Awoyemi D, Mandalia S, Bower M, Anderson M & Nelson M

Can haemoglobin drop replace rapid virological response in predicting a sustained virological response?

HIV Medicine 2012, 13 (suppl 1) 44.


CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.

2012 continued


**Clinical Effectiveness Group of British Association for Sexual Health and HIV (BASHH) and British HIV Association (BHIVA)**

*Int J STD AIDS.* 2012 June; 23 (6): 38108

McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, McGrath D, Farajallah A, Moyle G.

**Clinical Significance of Hyperbilirubinemia Among HIV-1-Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study.**

*AIDS Patient Care STDs.* 2012;26:259-64


**CNS effects of CCR5 inhibitor in HIV infected subjects: a pharmacokinetic and cerebral metabolite study**

*J Antimicrob Chemother.* 2012 Jan; 67 (1); 206-12

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabvin C, Post FA; UK CHIC/CKD* Study Group

**Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV positive patients**


Westrop S, Mandalia S, Moyle G, Bower M, Nelson M & Imami

**Comproped Influence of Patient Age, ART Duration and Time since HIV-1+ Diagnosis Delineates the Immune Profile of the Ageing Cohort**

*N. CROI 2012*


**Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.**


Chinthapalli S, Mandalia S, Jones R, Bower M & Nelson M

**Descriptive case series of eight HIV positive patients with foot stress fractures.**

*HIV Medicine* 2012, 13 ( suppl 1) S5


**Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals**

*AIDS:* 2012 Jul 17; 26 (22): 1399-401


**Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults**


**Efficacy and safety of rilpivirine in treatment naïve HIV-1 infected patients with hepatitis B virus/hepatitis C virus coinfections enrolled in the Phase III randomised, double blind ECHO and THRIVE trials**

*J Antimicrob Chemother.* 2012 Aug; 67 (*): 2020-8


**Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults**

*Antivir Ther.* 2012;17:861-8


**Exploring staff attitudes to routine HIV testing in non-traditional settings: a qualitative study in four healthcare facilities.**

*Sex Transm Infect* 2012 ;88:601-6

Mietloko S, Shahrabi Y, Hislop A, Harding V, Nelson M, Gotch F & Bower M.

**Ex-vivo recognition of immediate-early T cell epitopes within open reading frame ORF50 and K8 of Kaposi’s sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals**

*HIV Medicine* 2012, 13 ( suppl 1) 32.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansh L, Pillay D, Dunn D; on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

**Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.**

*J Antimicrob Chemother.* 2012 Apr;67(4):995-1000
Manley J, Dunning J, Nelson M, Bower M
**HIV associated gastric natural killer? T-cell lymphoma**
*Int J STD AIDS* 2012; Jan; 23 (1): 66-7

**HIV Testing in Non-Traditional Settings - The HINTS Study: A Multi-Centre Observational Study of Feasibility and Acceptability**

Bashford J, Atkins M, Bower M & Nelson M.  
**How commonly is JC virus detected in the cerebrospinal fluid of patients with HIV?**  
*HIV Medicine* 2012, 13 (suppl 1) 47

**Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals**  
*Clin Infect Dis.*, 2012 Feb 12; 54 (4): 556-9

**Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.**  
*HIV Clin Trials.* 2012;13:103-10

**Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.**  
*PloS One.* 2012;7(10):e47376

Salvinia Mletzko, Y Shahrabi, M Bower, K Hayward, V Harding, C Boshoff, A Benlahrech, and F Gotch.
**Modification of Dendritic Cell Function by Kaposi’s Sarcoma-associated Herpesvirus Suggests a Novel Immune Evasion Strategy**
*CROI 2012*

**Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study**  
*CROI 2012*

Garlassi E, Harding V, Allen H, Allin B, Lee N, Nelson M & Bower M.  
**Non-melanoma skin cancers among HIV-infected persons in the HAART-era**
*HIV Medicine* 2012, 13 (suppl 1) 34

**Non-uptake of highly active antiretroviral therapy among patients with a CD4 count <350 cells ul in the UK**  
*HIV Med 2012 Jan; 13 (1): 73-8

Bradshaw D, Pallawela S, Nelson M, Scott C, Day C  
**Otosyphilis: missed opportunities for early treatment**  
*Sex Transm Infect.* 2012 Sept 21

**PD-1 Expression on Natural Killers Cells and CD8 (+) T Cells During Chronic HIV-1 Infection**

**Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model**  

**Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.**
2012 continued


Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.

Tan J, Sonali S, Bower M, Smith B & Nelson M
Reasons for non-utilisation of a home delivery service among patients stabilised on antiretroviral therapy at 3 outpatient clinic sites
HIV Medicine 2012, 13 (suppl 1) 19.

Religion and HIV diagnosis among Africans living in London

Myers J, Rayment M, Sonecha S, Moyle G, Boffito M.
Room for manoeuvre when prescribing statins to dyslipidaemic patients on antiretroviral therapy.

Kumar N, Bower M, Nelson M
Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoos S, Davies G
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies

Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults
J Acquir Immune Defic Syndr. 2012;60:295-8

Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N.
The Effect of a 12-Week Course of Omega-3 Polysaturated Fatty Acids on Lipid Parameters in Hypertriglyceremic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial.
Clin Ther. 2012;34:67-76

Carr A, Hoy J, Pozniak A.
The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

Thomas Newsom-Davis, Paul Fox, Victoria Bradley, Alessia Dalla Pria, Mark Nelson, Mark Bower
The features and outcome of HIV-associated anal cancer in screened and unscreened populations
J Clin Oncol 30, 2012 (suppl; abstr e14574

The influence of antiretroviral therapy on QTc interval in an African cohort
Clin Infect Dis. 2012 Feb 1; 54 (3): 448-9

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir DRV/r monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors for patients with viral load <50 HIV-1 RNA copies/mL at baseline.

Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study
BMJ. 2012 Aug 21;345:e5253

Treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma does not improve outcome: a retrospective, multi-centre study
EHA 2012

UK national guideline on safer sex advice
International Journal of STD & AIDS 2012; 23

Vicriviroc plus optimised background therapy for treatment–experienced subjects with CCR5 HIV-1 infection: Final results of two randomised phase III trials

*J Infect. 2012 OCT; 65 (4): 326-35 2012*

**2011**


*A comparison of inpatient admissions in 2005 and 2010 at a tertiary centre*

*HIV Medicine 2011, 12 (Suppl 1), 68.*

S Westrop, G D’Souza, M Bower, B Gazzard, M Nelson and N Imami

*Algorithmic prediction for the identification of novel HLA-B*2705-restricted HIV-1 CD8 T-cell epitopes: assessment of epitope stability, affinity and specific T-cell profile*

*HIV Medicine 2011, 12 (Suppl 1), 29.*

A Scourfield, A Jackson, L Waters, J Dunning, S de Silva, N Francis, P Holmes, M Nelson and M Bower.

*An atypical presentation of Kaposi’s sarcoma.*

*HIV Medicine 2011, 12 (Suppl 1), 39.*

D Awoyemi, B Gazzard, M Bower, S Yau and M Nelson

*Antiretroviral drug dosing in renal impairment*

*HIV Medicine 2011, 12 (Suppl 1), 54.*

A Scourfield, L Waters, V Tittle, T Martin, N Rockwood, B Gazzard, M Bower and M Nelson

*Azathioprine use as a novel treatment for cryptococcal immune reconstitution and inflammatory syndrome in HIV*

*HIV Medicine 2011, 12 (Suppl 1), 45.*


*Early determination of treatment sensitivity in HIV-related Hodgkin lymphoma by FDG-PET/CT after two cycles of ABVD chemotherapy*

*GECAT (European Cooperative Study Group on AIDS and Tumors). Third international workshop on interim-PET in lymphoma, Menton, France 2011*


*Effect of raltegravir on rates of chemotherapy-induced neutropenia in HIV lymphomas*

*HIV Medicine 2011, 12 (Suppl 1), 36.*

R Robey, S Metzko, M Bower, R Meys, M Boffito, M Nelson, S Merchant, B Gazzard, C Boshoff and F Gotch

*Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi’s sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals*

*HIV Medicine 2011, 12 (Suppl 1), 23.*

Merchant S, Marouf A, Hachach-Haram N, Nelson M, Bower M and Newsom-Davis T

*Histopathological trends in HIV-associated lung cancer*

*Lung Cancer 2011; 71(S1), 11*
S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson, M Shanyinde, K Cwynarski, R Marcus, J de Vos, AM Young, M Tenant-Flowers, C Orkin, M Johnson, D Chilton, J Gribben, M Bow

**HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era**


Michael Furman, Pascual Balsalobre, Brady E. Beltran, Michele Bibas, Mark Bower, Weina Chen, Silvia Montoto, Roberto N. Miranda, Nahid M. Nanaji, Jose-Tomas Navarro, Adam C. Seegmiller, Julie M. Vose and Jorge J Castill

**HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study**


E Page, M Bower, D Kaplan, J Daruich, L Kikuchi, M Marques Molero, D Rimland, M Goetz, J Pineda8, K Marks, N Brau and M Nelson

**HIV-infected patients with hepatocellular carcinoma live longer if they have undetectable HIV RNA.**

HIV Medicine 2011, 12 (Suppl 1), 7. 2011


**Imaging of anorectal pathology by MR in people with HIV infection**

HIV Medicine 2011, 12 (Suppl 1), 38

S Mletzko, A Kyriakou, R Robey, M Bower, M Nelson, S Merchant, B Gazzard, C Boshoff and F Gotch

**Impaired dendritic cell (DC) function in Kaposi’s sarcoma-associated herpesvirus (KSHV) infections.**


S Westrop, D Lagos, M Bower, F Gotch, B Gazzard, C Boshoff and N Imami

**Increased incidence of multicentric Castleman’s disease in KSHV+ HIV-1+ individuals of Black African ethnicity may result from the higher frequency of the TLR4 single nucleotide polymorphism A299G.**


Haematologica

**Interim FDG-PET predicts response and progression free survival in patients with Hodgkin lymphoma and HIV infection**


Bulteel N, Bower M, Gazzard B, Mandalia S, Nelson M

**Is emtricitabine associated with reduced levels of the M184V mutation when compared with lamivudine?**

13th European AIDS Conference, Belgrade 2011

L Baber, S Sonecha, S Mandalia, M Bower, B Gazzard and M Nelson

**Patients’ willingness to switch from a single-tablet regimen (STR) to individual drugs as part of a potential cost-saving strategy**

HIV Medicine 2011, 12 (Suppl 1), 80.

Letang E, Lewis J, Bower M, Mosam A, Borok M, Naniche D, Newsom-Davis T, Shaik F, Campbell T and Easterbrook P.

**Predictors of paradoxical IRIS associated with Kaposi’s sarcoma in Sub-Saharan Africa and the UK: Developing a predictive score**

18th conference on retroviruses and opportunistic infections (CROI) 2011, 417.


**The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.**

PLoS One. 2011;6(12

B Lee, S Merchant, A Sita-Lumsden, B Gazzard, M Nelson and M Bower

**The incidence and correlates of paraneoplastic syndromes in 62 HIV-positive patients with Hodgkin’s Lymphoma.**

HIV Medicine 2011, 12 (Suppl 1), 37.


**The safety of Rituximab in HIV non-Hodgkin lymphoma patients with low CD4 cell counts**

6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.


**The safety of rituximab in patients with low CD4 cell counts**

HIV Medicine 2011, 12 (Suppl 1), 36.


**The use of faecal elastase to screen for pancreatic insufficiency in HIV-infected individuals**

HIV Medicine 2011, 12 (Suppl 1), 53


**The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.**

PLoS One. 2011;6(12
**Will earlier diagnosis of HIV reduce the presentation of serious opportunistic infections?**  

---

**2010**

**A Phase 2a randomized controlled trial of the short term activity, safety and pharmacokinetics of a novel NNRTI, RDEA806 in HIV-1 positive, antiretroviral-naive subjects.**  

**A single-center cohort experience of raltegravir in salvage patients failing therapy.**  

Gazzard B, Balkin A, Hill A.  
**Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.**  

**British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010**  

**Changes in adherence and patients’ perceptions of treatment in a 48 week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.**  
*AIDS Care* 2010: in press

Page EE, Cox A, Atkins M, Nelson MR.  
**Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells**  
*AIDS.* 2010 Jun;24(9):1267-71

---

**Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.**  
*Antiviral Res.* 2010 May;86(2):224-6

**Data linkage reduces loss to follow-up in an observational HIV cohort study.**  

Moyle G, Demasi R, Hill A.  
**Does earlier HIV RNA suppression provide long-term benefits?**  
*AIDS* 2010;24:1591-3

**Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension.**  

Pozniak AL, Morales-Ramirez J, Katabira E, Santoscoy M, Grinsztejn B, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group  
**Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.**  
*AIDS.* 2010 Jan 2;24(1):55-65.

**Epidemiology of herpes simplex virus types 2 and 1 amongst men who have sex with men (MSM) attending sexual health clinics in England and Wales: implications for HIV prevention and management**  
*Eurosurveillance* in press.
2010 continued

R Jones, A Menon-Johansson, AM Waters, AK Sullivan

eTriage – a novel, web-based triage and booking service: enabling timely access to sexual health clinics

Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma.
AIDS. 2010 Mar 27;24(6):851-6

Ridha E, Cookson H, Devitt E, Nelson M.
Febrile neutropenia in a HIV positive individual post-chemotherapy

HIV-associated colorectal cancer and the immunological effects of treatment
HIV Medicine 2010, 11 (suppl 1), 58.

Wilson J, Devitt E, Rampling T, Namulema E, Bower M & Nelson M
Increasing prevalence of pulmonary tuberculosis in HIV-infected individuals in Kampala, Uganda.
HIV Medicine 2010, 11 (suppl 1).

Interventions to increase access to STI services: A study of England’s ‘High Impact Changes’ across three central London clinics
STI 2010 in press

Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.

UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy

Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings
J Antimicrob Chemother. 2010 Apr;65(4):605-7

National Audit of Asymptomatic Screening in UK Genitourinary Medicine Clinics: Clinic Policies Audit.
Int J STD & AIDS in press

Rashid T, Meryon I, Mandalia S, Waters L, Devitt E, Bower M, Jones R & Nelson M
No association of vitamin D levels with individual antiretroviral agents, duration of HIV infection, alkaline phosphatase levels or bone mineral density findings
HIV Medicine 2010, 11 (suppl 1), 34

Non-germinal centre subtype of AIDS-related diffuse large B-cell lymphomas associated with improved survival.

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

Price H, Asboe D, Gazzard B, Fearnhill E. Pillay D, Dunn D: UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study
Positive and negative drug selection pressures on the N3481 connection domain mutation: new insights from in vivo data

Willis J, Jones R, Nwokolo N and Levy J
Protein and Creatine Supplements and Misdiagnosis of Kidney Disease
BMJ 2010;340:b5027

**Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study**


**Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?**


Williams J, Jones R, Nelson M, Barlow S, Short D, Savage P, Seckl M, Schmidt P & Bower M.

**Six cases of gestational trophoblastic tumours in women living with HIV.**

*HIV Medicine* 2010, 11 (suppl 1), 60.


**Spectrum of neurological disease in patients with discordant HIV-1 RNA levels in plasma and cerebrospinal fluid.**

*HIV Medicine* 2010, 11 (suppl 1), 34-5.

HIV-CAUSAL Collaboration

**The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals**

*AIDS.* 2010 Jan 2;24(1):123-37

Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.

**The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers**


**The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.**

*Antiviral Res.* 2010 May;86(2):227-9

Dunn D, von Wyl V, Price H, Asboe D.

**The impact of the 0-0 cell on measures of amino acid covariation**

*AIDS.* 2010 Jan 2;24(1):159-60. No abstract available


**The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml**

*AIDS.* 2010 Jan 16;24(2):223-30


**Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort**


**Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations**

*HIV Med.* 2010 Aug;11(7):432-8


**Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2.**

*J Acquir Immune Defic Syndr.* 2010 Aug 11

Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D

**Unselected hepatitis C screening of men who have sex with men attending sexual health clinics**


**Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.**


**Virological efficacy of darunavir/ritonavir monotherapy in clinical practice**

*HIV Medicine* 2010, 11 (suppl 1), 24
2009


A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis


A multicentre cohort experience with double-boosted protease inhibitors.


A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals


Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Holmes P, Low E, Bower M, Anderson M & Nelson M.

Acute hepatitis C is not associated with abnormal fibroscan readings
HIV Medicine 2009, 10 (Suppl1), 30

Ng SC, Gazzard B.

Advances in sexually transmitted infections of the gastrointestinal tract
Nat Rev Gastroenterol Hepatol. 2009 Aug 25

Powles S, Weir J, Francis N, Newsom-Davis T, Crook T, Boffito M, Nelson M & Bower M.

AIDS Kaposi’s sarcoma: outcomes in 254 consecutive patients diagnosed in modern times
HIV Medicine 2009, 10 (Suppl1), 10.

Walmsley S, Wilkin T, Moyle G

Antiretroviral rounds. Too many options?

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P

Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.

Woodcock H, Holmes P, Powles S, Dunning J, Bower M & Nelson M.

Burkitt’s non-Hodgkin lymphoma presenting as an isolated Bell’s palsy in HIV-positive patients
HIV Medicine 2009, 10 (Suppl1), 232009

Scott C, Azwa A, Cohen C, McIntyre M, Desmond N

Cat scratch disease: a diagnostic conundrum
Int J STD AIDS. 2009 Aug; 20(8) 585-6

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A.

Causes and consequences of incomplete HIV RNA suppression in clinical trials.


CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK.
Haematologica. 2009 Jun;94(6):875-80

Teague A, Scott C, Bower M, Gazzard B & Nelson M.

Clinical experience of raltegravir in salvage patients failing therapy, 48-week data
HIV Medicine 2009, 10 (Suppl1), 17

Moyle G, Rajicic N, Goodrich J, Mayer H, Valdez H.

Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials

Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV
J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):525-7


Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.

Scott C, Teague A, Bower M, Gazzard B & Nelson M
Darunavir/ritonavir once daily: a single-centre cohort experience
HIV Medicine 2009, 10 (Suppl1), 8

Soodalter J, Sousa M, Boffito M
Drug-drug interactions involving new antiretroviral drugs and drug classes.

Scourfield A, Waters L, Randell PA, McCormick K, Armenis K, Bower M & Nelson M

Effect of raltegravir on ALT in subjects coinfected with HIV and hepatitis C
HIV Medicine 2009, 10 (Suppl1), 31


Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

Pozniak A, Müller L, Salgo M, Jones JK, Larson P, Tweets D.
Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.

Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM & Goodier MR.

Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1 infected individuals.
AIDS 2009, 23: 29-34.


Excellent immunological recovery following the intensive chemotherapy CODOX-M IVAC, an effective therapy for HIV associated Burkitt’s lymphoma.
HIV Medicine 2009, 10 (Suppl1), 5

Dunning J, Myers J, Holmes P, Stuart-Buttle C, Bower M & Nelson M.

Experience with ritonavir/atazanavir in HIV-positive antiretroviral naive individuals commencing therapy.
HIV Medicine 2009, 10 (Suppl1), 18

Hill A, Sawyer W, Gazzard B.

Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data


FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease

Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ

Gastroenteropancreatic Neuroendocrine Tumors in Patients With HIV Infection: A Trans-Atlantic Series.


Highly active antiretroviral therapy and the incidence of Non-AIDS defining cancers in people with HIV infection

Price H, Sullivan AK

HIV opt out increases the offer and uptake of HIV tests in a GUM clinic

Gazzard B.

HIV testing in the UK
Lancet. 2009 Aug 1;374(9687):377

Vogel M, Nelson M.

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
Herasimtschuk A, Nelson M, Moyle G, Bower M & Imani N
Impact of recombinant human growth hormone on T-cell phenotype and function in vitro and in vivo during treated HIV-1 infection.
HIV Medicine 2009, 10 (Suppl1), 5.

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors

Interruption of antiretroviral therapy is associated with increased plasma cystatin C
AIDS. 2009 Jan 2;23(1):71-82.

Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study.

Methylation reversal in high grade B-cell lymphoma cell lines identifies novel epigenetic changes conserved between immunocompetent and HIV-positive hosts and others specific to HIV-associated lymphomas.
HIV Medicine 2009, 10 (Suppl1), 4.

Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S.
Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.

Dunning J, Nelson M.
Novel strategies to treat antiretroviral-naive HIV-infected patients.

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Sekar V, Lefebvre E, Mariën K, De Pauw M, Vangeneugden T, Pozniak A, Hoetelmans RM.
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.

Coyne KM, Pozniak AL, Lamorde M, Boffito M
Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

Prevention of atherosclerosis in patients living with HIV.

Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1.

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.


Rectal Chlamydia - a reservoir of undiagnosed infection in men who have sex with men.


Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir


Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.

AIDS. 2009 Aug 24;23(13):1689-99

Boyle BA, Cohen CJ, DeJesus E, Elior R, Frank I, Moyle GJ, Sax PE

Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use


Sexual health of adults working in pornographic films

Int J STD AIDS. 2009 Jul;20(7):508-9

Barton S

Sexually transmitted diseases by Dr Lisa Marr

AIDS Care. Vol 21. No. 4 April 2009


Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.


Steady state pharmacokinetics of plasma abacavir and intracellular carbovir triphosphate following abacavir 600mg once daily and 300g twice daily in HIV-infected subjects


Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.


Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance

AIDS. 2009 Jan 28;23(3):434-5. No abstract available

Teague A, Scott C, Youngstein T, Bower M, Gazzard B & Nelson M.

Switching to raltegravir: a successful strategy in treatment-experienced patients with toxicity? 48 week data

HIV Medicine 2009, 10 (Suppl1), 21.


The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.


The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma.


Coyne K, Mandalia S, McCullough S, Catalan J, Noestlinger C, Colebunders R, Asboe D

The International Index of Erectile Function: development of an adapted tool for use in HIV-positive men who have sex with men.

2009 continued

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.
The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals.

The relationship between prolonged antiretroviral therapy and cryptogenic liver disease.

The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease.

Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.

Westrop SJ, Qazi NA, Pido-Lopez J, Nelson MR, Gazzard B, Gotch FM, Imami N.
Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.

Vogel M, Page E, Nelson M, Rockstroh JK.
Treatment of acute hepatitis C in HIV-positive individuals: what are the challenges?

United Kingdom acquisition of HIV infection in African residents in London: more than previously thought.

Use of ezetimibe during HIV infection

2008

A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease.
AIDS. 2008 Feb 19;22(4):539-40

Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.

Boffito M, Abel S.
A review of the clinical pharmacology of maraviroc. Introduction

A single centre experience with darunavir/ritonavir (DRV/r) (600mg/100mg) and optimised background regimen in clinical practice.

Scott C, Staughton RC, Bunker CJ, Asboe D
Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy.

Acquisition of HIV infection in Africans resident in London: how much and how to assess
AIDS 2008; in press

Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi’s Sarcoma: A Multicenter Study
J Invest Dermatol. 2008 Jan 10

Stebbing J, Powles T, Bower M
AIDS-associated Kaposi’s sarcoma associated with a low viral load and a high CD4 cell count
AIDS. 2008; 22(4):551-2

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

Coyne KM, Barton SE, Smith NA, Cohen CE
Azithromycin without a prescription increases access and choice for patients
Int. J. STD & AIDS 2008;19:870


Gazzard BG; BHIVA Treatment Guidelines Writing Group

Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments
Cancer. 2008;112(5):955-961

Steel A, John L, Shamji MH, Henderson DC, Gotch FM, Gazzard BG, Kelleher P
CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy

J. Krell, M. Tuthill, V. Campbell, M. Nelson, P. Holmes, T. Powles, J. Stebbing, M. Bower
Cellular immunity following chemotherapy for systemic AIDS related non Hodgkin’s lymphoma (NHL)

Teague A, Scott C, Youngstein T, Bower M, Gazzard B & Nelson M
Clinical experience with raltegravir (MK-0518 or Isentress), with an optimised background regimen in highly treatment experienced patients

Holmes P, Nelson M, Bower M, Gazzard B & Barton S.
Coding and the clinician.

Daniels RH, Gazzard BG, Holmes P, Scourfield A, Bower M, Nelson M
Comparing the efficacy of Truvada® and Kivexa® combination therapy in HAART-naive individuals with different viral loads.

Gazzard BG.
Controversies in current treatment guidelines.

Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.

Does less frequent routine monitoring of patients on a stable, fully suppressed CART regimen lead to an increased risk of treatment failure?
2008 continued

Mihailidis C, Dunn D, Pillay D, Pozniak A
Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy
AIDS. 2008 Jan 30;22(3):427-30

Rosignoli G, Liptrott N, Imani N, Bower M, Gotch F & Owen A
Effect of PD1.3 single nucleotide polymorphism on CD4 and CD3 T cell counts in HAART-treated chronic HIV-1+ patients.

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.

Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imani N.
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up
J Immune Based Ther Vaccines. 2008; 6:7

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
AIDS. 2008 Sep 12;22(14):1779-87.

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
AIDS. 2008 Jan 11;22(2):275-9

Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ.
Episodic sexual transmission of HIV revealed by molecular phylogenetics.

Scott C, Khatib N, Bower M, Gazzard BG, Nelson M.
Etravirine use in clinical practice: 48-week data from a single centre cohort.

Clumeck N, Pozniak A, Raffi F; EACS Executive Committee.
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
HIV Med. 2008 Feb;9(2):65-71

Asghar AK, Bower M, Holmes P, Gazzard BG, Isenman H, Nelson M
Ezetimibe as lipid-lowering therapy for patients receiving HAART.

Burton C, Eccles-James I, Nelson M, Bower M, Gotch F & Imani N
Functional and phenotypic profiling of suppressive regulatory T cells in a cohort of HIV-1 Infected individuals.
HIV Medicine 2008, 9 (Suppl 1): 41

Macdonald DC, Nelson M, Bower M, Powles T.
Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.

Moyle G, Randell P
HIV and Cardiovascular risk

Harania RS, Karuru J, Nelson M, Stebbing J.
HIV, hepatitis B and hepatitis C coinfection in Kenya

Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ
HIV-associated multicentric Castleman’s disease

Barber TJ, Menon-Johanson A, Barton S
How can we remove barriers to HIV testing outside of GUM setting?
Br J Gen Pract. 2008 May; 58 (550): 365
Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Stebbing J, Powles T, Pantanowitz L


Immunological recovery in survivors following chemotherapy for AIDS related non Hodgkin’s lymphoma.
Blood. 2008 Jan 2;

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
J Infect Dis. 2008 Apr 15;197(8):1133-44

Naresh KN, Rice AJ, Bower M.
Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma


Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study
J Infect Dis. 2008 Apr 15;197(8):1133-44

Pozniak A.
Management of HIV: still a long way to go


Maraviroc for previously treated patients with R5 HIV-1 infection.


Missed opportunities for earlier HIV diagnosis within primary and secondary health care settings in the UK.


Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M.

Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs
2008 continued

Coyne, KM, Cohen CE, Smith NA, Barton SE.
Patient-delivery partner medication
Int. J. STD & AIDS 2008;19:646

Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.

Dickinson L, Boffito M, Khoo SH, Schutz M, Aarons LJ, Pozniak AL, Back DJ
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.

Sousa M, Pozniak A, Boffito M.
Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs.

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Antivir Ther. 2008;13(7):901-7

Boffito M, Miralles D, Hill A.
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and experienced patients.

V. Campbell, J. Krell, M. Stancliffe, M. Atkins, M. Habibi, M. Nelson, B. Gazzard, M. Bower
Plasma HHV8 DNA viral load as a tumour marker for multicentric Castleman’s disease MCD

Moyle G, Gatell J, Perno CF, Ratnasuwan W, Schechter M, Tsoukas C.
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.
AIDS Patient Care STDS 2008;22:459-71

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.
J Interferon Cytokine Res. 2008 Feb;28(2):89-100

Underwood J, Scourfield A, Bell C, Harding V, Bower M & Nelson M
Severe hepatotoxicity associated with darunavir
HIV Medicine 2008, 9 (Suppl 1): 18

Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Survival following HIV infection of a cohort followed up from seroconversion in the UK
AIDS. 2008 Jan 2;22(1):89-95

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE.
The face of HIV and AIDS: can we erase the stigma?
AIDS Care. 2008 Apr; 20 (4) 485-7

Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.
The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.

J.Krell, A. Bazeos, V. Campbell, V. Harding, T. Powles, J. Stebbing, S. Mandalia, M. Bower.
The incidence of HIV-associated multicentric Castleman’s disease

The risks and incidence of K65R and L74V mutations and subsequent virologic responses
Clin Infect Dis. 2008 Jan 1;46(1):96-100

Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG.
The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer.

The Seroprevalence of HTLV-1 amongst genitourinary attendees in South East London.

The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman’s disease

V. Campbell, J. Krell, A. Scourfield, S. Mandalia, M. Nelson, T. Powles, J.Stebbing, M. Bower
The use of antidepressants and risk of cancer in individuals infected with the human immunodeficiency virus

Cohen CE, Coyne KM, Mandalia S, Waters AM, Sullivan AK
Time to use text reminders in genitourinary medicine clinics

Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus
Cell Host Microbe. 2008 Nov 13;4(5):470-83

Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ.
Treatment of Altered Body Composition in HIV-Associated Lipodystrophy: Comparison of Rosiglitazone, Pravastatin, and Recombinant Human Growth Hormone

Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.

Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes.
2008 continued

Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M

**Use of antidepressants and risk of cancer in individuals infected with HIV**

*J Clin Oncol. 2008 May 10;26(14):2305-10*


**Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen**

*AIDS. 2008 Nov 12;22(17):2279-89.*

Ancok B, Bower M, Gazzard BG, Nelson M

**Vitamin D deficiency in the in-patients HIV population: cause or effect?**


Bhattacharya R, Barton SE, Catalan J

**When good news is bad news: psychological impact of false positive diagnosis of HIV**

*AIDS Care. 2008 May; 20(5): 560-4*